Onabotulinumtoxin  	Onabotulinumtoxin  	 NNP	B-NP
A  	A  	 NNP	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
migraine  	migraine  	 JJ	I-NP
INTRODUCTION 	INTRODUCTION 	 NNP	I-NP
.  	.  	 .	O
Chronic  	Chronic  	 JJ	B-NP
migraine  	migraine  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
complication  	complication  	 NN	B-NP
of  	of  	 IN	O
migraine 	migraine 	 NN	O
.  	.  	 .	O
Its  	Its  	 PRP$	O
management  	management  	 NN	O
is  	is  	 VBZ	O
complex  	complex  	 JJ	O
and  	and  	 CC	O
difficult 	difficult 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
is  	is  	 VBZ	O
based  	based  	 VBN	O
essentially  	essentially  	 RB	O
on  	on  	 IN	O
preventive  	preventive  	 JJ	B-NP
measures 	measures 	 NNS	I-NP
.  	.  	 .	O
AIM 	AIM 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
analyse  	analyse  	 VB	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
Onabotulinumtoxin  	Onabotulinumtoxin  	 NNP	B-NP
A  	A  	 NNP	I-NP
( 	( 	 -LRB-	O
OnabotA 	OnabotA 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
migraine 	migraine 	 NN	O
,  	,  	 ,	O
especially  	especially  	 RB	O
in  	in  	 IN	O
its  	its  	 PRP$	O
chronic  	chronic  	 JJ	B-NP
form 	form 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
method  	method  	 NN	O
of  	of  	 IN	O
administration 	administration 	 NN	B-NP
,  	,  	 ,	O
its  	its  	 PRP$	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action 	action 	 NN	O
,  	,  	 ,	O
its  	its  	 PRP$	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
and  	and  	 CC	O
its  	its  	 PRP$	O
possible  	possible  	 JJ	O
indications  	indications  	 NNS	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
DEVELOPMENT 	DEVELOPMENT 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
conducts  	conducts  	 VBZ	O
a  	a  	 DT	O
thorough  	thorough  	 JJ	O
review  	review  	 NN	O
of  	of  	 IN	O
all  	all  	 PDT	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
literature  	literature  	 NN	O
that  	that  	 WDT	O
have  	have  	 VBP	O
used  	used  	 VBN	O
OnabotA  	OnabotA  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
migraine 	migraine 	 NN	O
,  	,  	 ,	O
both  	both  	 DT	O
in  	in  	 IN	O
its  	its  	 PRP$	O
episodic  	episodic  	 NN	O
and  	and  	 CC	O
its  	its  	 PRP$	O
chronic  	chronic  	 JJ	B-NP
forms 	forms 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
outcomes  	outcomes  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
chronic  	chronic  	 JJ	B-NP
form  	form  	 NN	I-NP
are  	are  	 VBP	O
analysed  	analysed  	 VBN	O
in  	in  	 IN	O
detail 	detail 	 NN	O
.  	.  	 .	O
CONCLUSIONS 	CONCLUSIONS 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
studies  	studies  	 NNS	O
in  	in  	 IN	O
phase  	phase  	 NN	O
III 	III 	 NNP	O
,  	,  	 ,	O
OnabotA  	OnabotA  	 NNP	B-NP
has  	has  	 VBZ	O
proved  	proved  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
migraine 	migraine 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
significant  	significant  	 JJ	O
reductions  	reductions  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
mean  	mean  	 JJ	O
frequency  	frequency  	 NN	O
of  	of  	 IN	O
days  	days  	 NNS	O
with  	with  	 IN	O
headaches 	headaches 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
headache  	headache  	 JJ	B-NP
episodes 	episodes 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
days  	days  	 NNS	O
with  	with  	 IN	O
migraine  	migraine  	 NN	O
or  	or  	 CC	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
severe  	severe  	 JJ	O
disability 	disability 	 NN	O
,  	,  	 ,	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
other  	other  	 JJ	O
parameters 	parameters 	 NNS	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
also  	also  	 RB	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
subgroup  	subgroup  	 NN	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
symptomatic  	symptomatic  	 JJ	B-NP
headache  	headache  	 JJ	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
medication  	medication  	 VB	B-NP
abuse 	abuse 	 NN	I-NP
.  	.  	 .	O
OnabotA  	OnabotA  	 NNP	B-NP
has  	has  	 VBZ	O
proved  	proved  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
safe  	safe  	 JJ	O
and  	and  	 CC	O
well  	well  	 RB	O
tolerated  	tolerated  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
indication 	indication 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
foreseeable 	foreseeable 	 JJ	O
,  	,  	 ,	O
usually  	usually  	 RB	O
mild  	mild  	 JJ	O
or  	or  	 CC	O
moderate 	moderate 	 JJ	O
,  	,  	 ,	O
transitory  	transitory  	 JJ	B-NP
side  	side  	 NN	I-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
sum 	sum 	 NN	O
,  	,  	 ,	O
OnabotA  	OnabotA  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
safe 	safe 	 JJ	O
,  	,  	 ,	O
well-tolerated  	well-tolerated  	 JJ	O
alternative  	alternative  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
preventive  	preventive  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
chronic  	chronic  	 JJ	I-NP
migraine 	migraine 	 NN	I-NP
.  	.  	 .	O
